HaDEA - Vital Signs

Sign in Subscribe

HaDEA

A collection of 2 posts

Inside EU Health: EMA recommends five new medicines: Gilead HIV drug dispute; EU funds for innovative treatments; WHO extends PABS negotiations

Inside EU Health

Inside EU Health: EMA recommends five new medicines: Gilead HIV drug dispute; EU funds for innovative treatments; WHO extends PABS negotiations

EMA recommends five new medicines for approval; MSF denied access to Gilead HIV-prevention drug; Europe invests €244 million to fast-track next-generation treatments for deadly infections; WHO members extend negotiations on pathogen sharing framework

Inside EU Health: Parliament pushes for bolder CMA; cardiovascular disease costs 2% EU GDP; EU backs rapid ‘test-before-treat’ diagnostic

Inside EU Health

Inside EU Health: Parliament pushes for bolder CMA; cardiovascular disease costs 2% EU GDP; EU backs rapid ‘test-before-treat’ diagnostic

Parliament pushes for a more ambitious and European Critical Medicines Act; report estimates that cardiovascular disease costs the EU 2% of GDP; and Commission backs rapid ‘Test Before Treat’ technology to reduce misuse of antibiotics